Head-to-head · computed 2026-08-11
bmiMD vs Direct Meds
bmiMD: bmiMD is a compounded GLP-1 telehealth platform notable for flat per-dose pricing — the rate stays the same whether you're at 2.5 mg or 15 mg — and one of the widest plan-tier menus in the market. Its $99/mo semaglutide and $139/mo tirzepatide on the twelve-month plan are the lowest annualized figures in the dataset for both molecules. Direct Meds: Direct Meds offers compounded GLP-1s in multiple formats — sublingual and injectable — with all-inclusive pricing verified on its own product pages. Semaglutide runs $249–$297/mo and tirzepatide $299–$399/mo depending on format; the lower figures are for sublingual delivery.
Tirzepatide
| bmiMD | Direct Meds | |
|---|---|---|
| All-in maintenance | $179/mo | $399/mo |
| Best plan rate | $139/mo | $399/mo |
| 12-month total | $1,668 | $4,788 |
| Status | Reported · 2026-07-14 | Reported · 2026-07-25 |
The arithmetic
On the figures our desk holds, bmiMD's $179 a month undercuts Direct Meds's $399 by $220 a month at the 10 mg/wk maintenance basis — $2,640 across a year. bmiMD's figure is reported (captured 2026-07-14) and Direct Meds's is reported (captured 2026-07-25); a status below 'verified' means our independent checkout capture is still pending, so treat the gap as the best current evidence rather than settled fact.
bmiMD's tirzepatide ladder runs $179 a month billed monthly, $159 a month on a three-month plan, $149 a month on a six-month plan, and $139 a month on a twelve-month plan. Direct Meds's runs $399 a month billed monthly. On the twelve-month basis bmiMD's $1,668 beats Direct Meds's $4,788 by $3,120 — with the winner's figure resting on a committed twelve-month plan, a structural difference that matters if you might stop early.
Semaglutide
| bmiMD | Direct Meds | |
|---|---|---|
| All-in maintenance | $129/mo | $297/mo |
| Best plan rate | $99/mo | $297/mo |
| 12-month total | $1,188 | $3,564 |
| Status | Reported · 2026-07-14 | Reported · 2026-07-25 |
The arithmetic
On the figures our desk holds, bmiMD's $129 a month undercuts Direct Meds's $297 by $168 a month at the 2.4 mg/wk maintenance basis — $2,016 across a year. bmiMD's figure is reported (captured 2026-07-14) and Direct Meds's is reported (captured 2026-07-25); a status below 'verified' means our independent checkout capture is still pending, so treat the gap as the best current evidence rather than settled fact.
bmiMD's semaglutide ladder runs $129 a month billed monthly, $119 a month on a three-month plan, $109 a month on a six-month plan, and $99 a month on a twelve-month plan. Direct Meds's runs $297 a month billed monthly. On the twelve-month basis bmiMD's $1,188 beats Direct Meds's $3,564 by $2,376 — with the winner's figure resting on a committed twelve-month plan, a structural difference that matters if you might stop early.
Where the structures genuinely differ
On dose economics, bmiMD is dose-flat — the price survives titration — while Direct Meds's pricing can move with the dose, a difference that compounds through a standard escalation schedule and matters most to buyers expecting to reach the higher maintenance doses.
Structure, side by side
bmiMD
- MembershipNone
- Dose policyFlat — same price at every dose, across all plan lengths
- CommitmentMonthly, 3-month, 6-month, or 12-month plans; price varies by term, not by dose
- CancellationPer provider terms; confirm cancellation policy at enrollment
- PharmacyNamed 503A pharmacy partner (specific pharmacy not publicly identified on pricin
Direct Meds
- MembershipNone
- Dose policyAll-inclusive per format; injection and sublingual priced separately
- CommitmentMonthly (no commitment indicated)
- CancellationPer provider terms
- PharmacyPartner 503A pharmacy (not publicly named)
What our desk is watching on each
bmiMD: bmiMD's 12-month semaglutide plan at $99/mo is the lowest annualized sema figure in our dataset, beating NexLife's $119/mo and Oak's $133 m2m. Month-to-month sema at $129 also beats Oak's $133, making bmiMD the new m2m sema leader. Tirzepatide 12-month at $139 ties NexLife. Figures are reported status from RangeYourself's July 2026 first-party captures; our independent checkout is pending.
Direct Meds: Pricing varies by format and page; product-page 'all-inclusive' rates differ from homepage promo cards. Rank is based on injectable rate as primary. Reported status — RangeYourself verified 2026-07-25 on Direct Meds' own product pages.
Questions people ask
Is bmiMD or Direct Meds cheaper in 2026?
The tirzepatide and semaglutide verdict blocks above give the computed answer at the maintenance basis, with the verification status of each figure; the short version is that whichever program's all-in monthly number is lower on this page is cheaper on the evidence we hold today, and both rows carry capture dates so you can judge freshness.
What does bmiMD vs Direct Meds miss that checkout will show?
Taxes, state availability, current promotions, and any dose surcharge introduced after our capture date. Screenshot the order summary before paying — that capture, not any comparison page, is your contract.
Why do you compare at the maintenance dose instead of the starting dose?
Because starter pricing lasts one or two months and maintenance pricing lasts the rest of the year; comparing starts against maintenances is the single most common way GLP-1 comparisons mislead.
What do bmiMD and Direct Meds cost over a full year of tirzepatide?
On the plans our database holds, a year of tirzepatide runs $1,668 at bmiMD and $4,788 at Direct Meds — computed from each program's best published twelve-month route, with promotional figures labeled in the sections above and every number carrying its capture date.
Both records live in the normalized database; re-run the math yourself from the downloads. Full record pages: bmiMD · Direct Meds. Official sites: bmiMD ↗ · Direct Meds ↗. Nothing here is medical advice.